z-logo
open-access-imgOpen Access
Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment
Author(s) -
Ihab Hajjar,
Maureen Okafor,
Darius McDaniel,
Malik Obideen,
Elizabeth Dee,
Mahsa Shokouhi,
Arshed A. Quyyumi,
Allan I. Levey,
Felicia C. Goldstein
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.12252
Subject(s) - candesartan , lisinopril , neurocognitive , medicine , montreal cognitive assessment , randomized controlled trial , trail making test , psychology , cardiology , physical therapy , cognition , blood pressure , neuropsychology , angiotensin ii , cognitive impairment , psychiatry , angiotensin converting enzyme
Key Points Question What are the comparative neurocognitive effects of an angiotensin receptor blocker, candesartan, and an angiotensin-converting enzyme inhibitor, lisinopril, on adults with hypertension and executive mild cognitive impairment? Findings In this randomized clinical trial of 176 adults with hypertension, 12-month treatment with candesartan was associated with improvement in executive function and episodic memory compared with lisinopril. Meaning These findings suggest that among older adults with hypertension and mild cognitive impairment, treatment with candesartan provided better neurocognitive effects compared with lisinopril despite equivalent blood pressure levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom